234 related articles for article (PubMed ID: 1726345)
1. Human cytotoxic effector cells: definition and analysis of activity.
Ortaldo JR
Allergol Immunopathol (Madr); 1991; 19(4):145-56. PubMed ID: 1726345
[TBL] [Abstract][Full Text] [Related]
2. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns.
Doherty DG; Norris S; Madrigal-Estebas L; McEntee G; Traynor O; Hegarty JE; O'Farrelly C
J Immunol; 1999 Aug; 163(4):2314-21. PubMed ID: 10438977
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killing by human intestinal lymphocytes.
Ebert EC; Roberts AI
Cell Immunol; 1993 Jan; 146(1):107-16. PubMed ID: 7678783
[TBL] [Abstract][Full Text] [Related]
6. Natural killer (NK) cell subsets in the mouse. NK-1.1+/LGL-1+ cells restricted to lysing NK targets, whereas NK-1.1+/LGL-1- cells generate lymphokine-activated killer cells.
Mason LH; Mathieson BJ; Ortaldo JR
J Immunol; 1990 Jul; 145(2):751-9. PubMed ID: 2365999
[TBL] [Abstract][Full Text] [Related]
7. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
Lu PH; Negrin RS
J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
[TBL] [Abstract][Full Text] [Related]
8. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
Drobyski WR; LeFever AV; Truitt RL
Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
[TBL] [Abstract][Full Text] [Related]
9. Targeted cytotoxic cells in human peripheral blood lymphocytes.
Garrido MA; Perez P; Titus JA; Valdayo MJ; Winkler DF; Barbieri SA; Wunderlich JR; Segal DM
J Immunol; 1990 Apr; 144(8):2891-8. PubMed ID: 1691221
[TBL] [Abstract][Full Text] [Related]
10. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
11. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells.
Arancia G; Malorni W; Donelli G
Ann Ist Super Sanita; 1990; 26(3-4):369-84. PubMed ID: 2151107
[TBL] [Abstract][Full Text] [Related]
12. The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes.
Schwarz RE; Hiserodt JC
J Immunol; 1988 Nov; 141(10):3318-23. PubMed ID: 3263421
[TBL] [Abstract][Full Text] [Related]
13. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
15. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
16. Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity.
Reiter Z
Crit Rev Immunol; 1993; 13(1):1-34. PubMed ID: 8466640
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations.
Ballas ZK; Rasmussen W
J Immunol; 1990 Jan; 144(1):386-95. PubMed ID: 2104892
[TBL] [Abstract][Full Text] [Related]
19. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
Ortaldo JR; Frey J; Takeshita T; Sugamura K
Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
[TBL] [Abstract][Full Text] [Related]
20. Modulation of lymphokine release and cytolytic activities by activating peripheral blood lymphocytes via CD2.
Valentin H; Groux H; Gelin C; Chretien I; Bernard A
J Immunol; 1990 Feb; 144(3):875-82. PubMed ID: 1967277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]